BioCentury | Aug 4, 2018
Finance

Functions of formulation

Halozyme Therapeutics Inc. is quickly expanding the reach of its Enhanze platform on the back of regulatory approvals for products that are now gaining market share, plus a playbook for streamlined early development it can...
BioCentury | Nov 18, 2013
Strategy

Shire goes vertical

The proposed $4.2 billion buyout of ViroPharma Inc. fits Shire plc 's long-standing growth through acquisition model, but the new CEO also wants to focus on internal R&D in rare diseases. This deal is an...
BioCentury | Oct 7, 2013
Finance

3Q Stock Wrap-Up: Make it a double

For the second time this year, all market cap segments closed the quarter in the black. Large caps valued at $5 billion and above gained ground for the fifth consecutive quarter. They added 12%, and...
BC Week In Review | Aug 5, 2013
Clinical News

Subcutaneous Cinryze: Phase IIb discontinued

ViroPharma discontinued a double-blind, crossover, international Phase IIb trial evaluating subcutaneous Cinryze in combination with Halozyme's recombinant human PH20 hyaluronidase ( rHuPH20 ) due to "an unexpected incidence and titer of non-neutralizing anti-rHuPH20 antibodies." ViroPharma said the...
BioCentury | Aug 5, 2013
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 8/2 cls Cubist Pharmaceuticals Inc. (NASDAQ:CBST) Credit Suisse Jason Kantor Upgrade Outperform (from neutral) 13% $63.10 Kantor also raised his target to $69 from...
BioCentury | Aug 5, 2013
Finance

Deciphering Dicerna's future

Dicerna Pharmaceuticals Inc .'s $60 million series C round last week attracted a syndicate of crossover investors that could usher the second-generation RNAi play to a public listing by this time next year. New investor...
BioCentury | Aug 5, 2013
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) gained $5.67 to $82.90 on Tuesday after reporting $6.5 million in 2Q13 sales of Juxtapid lomitapide for homozygous familial hypercholesterolemia (hoFH), beating the Street's estimate of $4.3 million. On...
BC Extra | Aug 2, 2013
Clinical News

ViroPharma discontinuing trial for subcutaneous Cinryze/rHuPH20

Halozyme Therapeutics Inc. (NASDAQ:HALO) slipped $1.19 (14%) to $7.32 on Thursday after ViroPharma Inc. (NASDAQ:VPHM) said it is discontinuing a Phase IIb trial evaluating subcutaneous Cinryze in combination with Halozyme's recombinant human PH20 hyaluronidase ( rHuPH20...
BC Week In Review | Dec 24, 2012
Clinical News

Subcutaneous Cinryze: Phase IIb started

ViroPharm began a double-blind, crossover, international Phase IIb trial to evaluate subcutaneous Cinryze in combination with Halozyme's recombinant human PH20 hyaluronidase ( rHuPH20 ) for 8 weeks in about 40 adolescent and adult patients. Patients will receive...
BC Week In Review | Sep 24, 2012
Clinical News

Subcutaneous Cinryze: Phase II resumed

Halozyme and partner ViroPharma said FDA lifted a clinical hold on a Phase II trial of subcutaneous Cinryze in combination with Halozyme's recombinant human PH20 hyaluronidase ( rHuPH20 ) for HAE. The partners said they can restart...
Items per page:
1 - 10 of 21